Cargando…

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part II

The development of in vitro/in vivo translational methods for synergistically acting drug combinations is needed to identify the most effective therapeutic strategies. We performed PBPK/PD modelling for siremadlin, trametinib, and their combination at various dose levels and dosing schedules in an A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Witkowski, Jakub, Polak, Sebastian, Rogulski, Zbigniew, Pawelec, Dariusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570053/ https://www.ncbi.nlm.nih.gov/pubmed/36233247 http://dx.doi.org/10.3390/ijms231911939

Ejemplares similares

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part III
por: Witkowski, Jakub, et al.
Publicado: (2023)

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part I
por: Witkowski, Jakub, et al.
Publicado: (2022)

Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model
por: Kuepfer, L, et al.
Publicado: (2016)

PBPK-PD modeling for the preclinical development and clinical translation of tau antibodies for Alzheimer’s disease
por: Bloomingdale, Peter, et al.
Publicado: (2022)

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers
por: Hata, Aaron N, et al.
Publicado: (2017)

A four-compartment PBPK heart model accounting for cardiac metabolism - model development and application
por: Tylutki, Zofia, et al.
Publicado: (2017)

Analysis of biomarker utility using a PBPK/PD model for carbaryl
por: Phillips, Martin B., et al.
Publicado: (2014)

Approaches to developing alternative and predictive toxicology based on PBPK/PD and QSAR modeling.
por: Yang, R S, et al.
Publicado: (1998)

Development and Performance Verification of the PBPK Model for Antazoline and Its Metabolite and Its Utilization for Pharmacological Hypotheses Formulating
por: Wiśniowska, Barbara, et al.
Publicado: (2022)

Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells
por: Arafeh, Rand, et al.
Publicado: (2017)

Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence
por: Rostami‐Hodjegan, Amin
Publicado: (2017)

MEK inhibitor PD0325901 and vitamin C synergistically induce hypomethylation of mouse embryonic stem cells
por: Li, Cuiping, et al.
Publicado: (2016)

Comprehensive Parent–Metabolite PBPK/PD Modeling Insights into Nicotine Replacement Therapy Strategies
por: Kovar, Lukas, et al.
Publicado: (2020)

Performance Evaluation of Montelukast Pediatric Formulations: Part II — a PBPK Modelling Approach
por: Guimarães, Mariana, et al.
Publicado: (2022)

Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
por: Dixon-Douglas, Julia R., et al.
Publicado: (2022)

Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma
por: Posch, C, et al.
Publicado: (2015)

FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma
por: Tarin, Malcy, et al.
Publicado: (2023)

Quality Control Dissolution Data Is Biopredictive for a Modified Release Ropinirole Formulation: Virtual Experiment with the Use of Re-Developed and Verified PBPK Model
por: Shuklinova, Olha, et al.
Publicado: (2022)

MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma
por: Forschner, Andrea, et al.
Publicado: (2020)

MDM4 Isoform Expression in Melanoma Supports an Oncogenic Role for MDM4-A
por: Alatawi, Abdullah, et al.
Publicado: (2021)

Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals
por: Tylutki, Zofia, et al.
Publicado: (2018)

Author Correction: Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells
por: Arafeh, Rand, et al.
Publicado: (2019)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
por: Huynh, Sandra, et al.
Publicado: (2020)

Sex-Specific Associations of MDM2 and MDM4 Variants with Risk of Multiple Primary Melanomas and Melanoma Survival in Non-Hispanic Whites
por: Ward, Sarah V., et al.
Publicado: (2023)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK
por: Wagner, C, et al.
Publicado: (2015)

Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom?
por: Frechen, Sebastian, et al.
Publicado: (2022)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

Advanced In Vivo Prediction by Introducing Biphasic Dissolution Data into PBPK Models
por: Denninger, Alexander, et al.
Publicado: (2023)

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
por: Laroche-Clary, Audrey, et al.
Publicado: (2017)

Inhibition of glioblastoma dispersal by the MEK inhibitor PD0325901
por: Shannon, Stephen, et al.
Publicado: (2017)

Anti-Melanoma Activities of Haspin Inhibitor CHR-6494 Deployed as a Single Agent or in a Synergistic Combination with MEK Inhibitor
por: Han, Lili, et al.
Publicado: (2017)

The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
por: Ingelshed, Katrine, et al.
Publicado: (2022)

PBPK modeling and simulation in drug research and development
por: Zhuang, Xiaomei, et al.
Publicado: (2016)

Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III–IV Melanoma: A Systematic Review and Meta-Analysis
por: Liu, Ye, et al.
Publicado: (2021)

Clinical and Pathological Relevance of Drug-induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF/MEK Inhibitors
por: RAMONDETTA, Alice, et al.
Publicado: (2020)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

MEK targeting in N-RAS mutated metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2014)

Trametinib: a MEK inhibitor for management of metastatic melanoma
por: Lugowska, Iwona, et al.
Publicado: (2015)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_39i5l163dcg8ao6ootoaiqdq2j